We are thrilled to announce that Valeos Pharma A/S has officially received the Good Manufacturing Practice (GMP) licence for our medicinal cannabis operations. This significant milestone comes after a rigorous and successful inspection by the Danish Medicines Agency, underscoring our commitment to excellence in pharmaceutical standards.
The GMP licence is a testament to our dedication to maintaining the highest quality and safety in our production processes. It reflects our adherence to stringent regulations and protocols designed to ensure that our medicinal cannabis products meet the strictest standards of purity, potency, and consistency.
The inspection by the Danish Medicines Agency was thorough and comprehensive, examining every aspect of our operations. Their approval highlights the robustness of our manufacturing practices, the efficacy of our quality control systems, and our unwavering commitment to patient safety.
Achieving this licence is not just a regulatory requirement but a cornerstone of our mission to provide patients with reliable and effective medicinal cannabis products. It reaffirms our role as a trusted partner in the healthcare community, dedicated to advancing the therapeutic benefits of medicinal cannabis through innovation and rigorous scientific standards.
As we move forward, we remain committed to maintaining these high standards and continuing to provide safe, high-quality medicinal cannabis products.
Valeos Pharma A/S – Advancing Health, Ensuring Quality
Comments